Dushyant Viswanathan, MD
Internal Medicine · Woodland Hills, CANPI 1285897421
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $4,600 of the $5,921 with a category attached, or 77.7%. Concordia Pharmaceuticals Inc. accounts for 73.4% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $5,808 and has fallen 98.4% since, to $95 in 2024. Among internal medicine clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 24 payments — averaging $246.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Concordia Pharmaceuticals Inc.$4K
- Napo Pharmaceuticals Inc$1K
- Cleerly, Inc.$95
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$18
What the payments were for
- Speaking & faculty fees$4,60078%
- Travel & lodging$70612%
- Food & beverage$61610%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Concordia Pharmaceuticals Inc. | 17 | $4,345 |
| Napo Pharmaceuticals Inc | 5 | $1,463 |
| Cleerly, Inc. | 1 | $95 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,921 in reported general payments places this provider in the 90th percentile of 13,581 internal medicine providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 140 | $81,549 |
| JardianceEmpagliflozin | 71 | $66,791 |
| OzempicSemaglutide | 58 | $60,981 |
| Hydrocortisone | 31 | $50,958 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 56 | $35,955 |
| MounjaroTirzepatide | 22 | $30,177 |
| JanuviaSitagliptin Phosphate | 43 | $25,120 |
| RybelsusSemaglutide | 20 | $24,534 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 11 | $18,144 |
| Diflorasone Diacetate | 29 | $17,318 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 31 | $15,521 |
| FarxigaDapagliflozin Propanediol | 22 | $12,744 |
| LinzessLinaclotide | 22 | $12,144 |
| XareltoRivaroxaban | 21 | $12,129 |
| Cyclosporine | 29 | $11,061 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Woodland Hills
- Andrew ChengSouth San Francisco$55.1M
- Tung NgoNewport Beach$4.9M
- Christian EversullStanford$2.9M
- Christian SandrockSacramento$2.1M
- Hatim HusainSan Diego$2M
- Teck LingPalo Alto$1.1M
- Hyong Kimla Jolla$1M
- Rohit Loombala Jolla$965K
- Fred CohenSan Francisco$929K
- Steven EdelmanSan Diego$863K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.